Full Lumryz Approval Unlikely - Avadel Pharmaceuticals (AVDL) PT Raised to $5 at Stifel on FT218 Tentative Approval but Hold Rating Maintained
Tweet Send to a Friend
Stifel analyst Paul Matteis raised the price target on Avadel Pharmaceuticals (NASDAQ: AVDL) to $5.00 (from $2.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
